{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047406","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.609348+00:00","generated_at":"2026-05-30T00:53:16.849040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway","bullets":["Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.","Net product revenue of $0.6M from XOLREMDI (mavorixafor) for WHIM syndrome, launched April 2024.","Positive Phase 2 results: mavorixafor durably increased absolute neutrophil counts and enabled G-CSF reduction in chronic neutropenia.","Phase 3 4WARD trial on track to fully enroll mid-2025; regulatory approvals in ~85% of targeted countries.","Cash $135.8M, sufficient into late 2025 (excludes potential XOLREMDI revenue)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047406","json":"https://secwatch.observer/filing/0001628280-24-047406.json","markdown":"https://secwatch.observer/filing/0001628280-24-047406.md","text":"https://secwatch.observer/filing/0001628280-24-047406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/0001628280-24-047406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/xfor-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:16.849040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}